These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20219934)

  • 1. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect.
    Brandler S; Lepelley A; Desdouits M; Guivel-Benhassine F; Ceccaldi PE; Lévy Y; Schwartz O; Moris A
    J Virol; 2010 May; 84(10):5314-28. PubMed ID: 20219934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
    Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
    Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified vaccinia virus Ankara-infected dendritic cells present CD4+ T-cell epitopes by endogenous major histocompatibility complex class II presentation pathways.
    Thiele F; Tao S; Zhang Y; Muschaweckh A; Zollmann T; Protzer U; Abele R; Drexler I
    J Virol; 2015 Mar; 89(5):2698-709. PubMed ID: 25520512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
    Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
    Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS.
    Guerra S; González JM; Climent N; Reyburn H; López-Fernández LA; Nájera JL; Gómez CE; García F; Gatell JM; Gallart T; Esteban M
    J Virol; 2010 Aug; 84(16):8141-52. PubMed ID: 20534857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vector replication and expression of HIV-1 antigens by the HIV/AIDS vaccine candidate MVA-B is not affected by HIV-1 protease inhibitors.
    García-Arriaza J; Arnáez P; Jiménez JL; Gómez CE; Muñoz-Fernández MÁ; Esteban M
    Virus Res; 2012 Aug; 167(2):391-6. PubMed ID: 22659488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors.
    Zhang X; Cassis-Ghavami F; Eller M; Currier J; Slike BM; Chen X; Tartaglia J; Marovich M; Spearman P
    J Virol; 2007 Jul; 81(13):7022-33. PubMed ID: 17409140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
    García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
    PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
    Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
    Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NK cells are primed by ANRS MVA(HIV)-infected DCs, via a mechanism involving NKG2D and membrane-bound IL-15, to control HIV-1 infection in CD4+ T cells.
    Moreno-Nieves UY; Didier C; Lévy Y; Barré-Sinoussi F; Scott-Algara D;
    Eur J Immunol; 2014 Aug; 44(8):2370-9. PubMed ID: 24777763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C.
    Gómez CE; Perdiguero B; Jiménez V; Filali-Mouhim A; Ghneim K; Haddad EK; Quakkelaar ED; Delaloye J; Harari A; Roger T; Duhen T; Sékaly RP; Melief CJ; Calandra T; Sallusto F; Lanzavecchia A; Wagner R; Pantaleo G; Esteban M
    PLoS One; 2012; 7(4):e35485. PubMed ID: 22536391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficient Induction of Cytotoxic T Cells by Viral Vector Vaccination Requires STING-Dependent DC Functions.
    Barnowski C; Ciupka G; Tao R; Jin L; Busch DH; Tao S; Drexler I
    Front Immunol; 2020; 11():1458. PubMed ID: 32765505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
    Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
    Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C.
    Burgers WA; Shephard E; Monroe JE; Greenhalgh T; Binder A; Hurter E; Van Harmelen JH; Williamson C; Williamson AL
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):195-206. PubMed ID: 18240957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
    Gómez CE; Abaitua F; Rodríguez D; Esteban M
    Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens.
    Perdiguero B; Gómez CE; Nájera JL; Sorzano CO; Delaloye J; González-Sanz R; Jiménez V; Roger T; Calandra T; Pantaleo G; Esteban M
    PLoS One; 2012; 7(10):e48524. PubMed ID: 23119046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
    García-Arriaza J; Nájera JL; Gómez CE; Tewabe N; Sorzano CO; Calandra T; Roger T; Esteban M
    PLoS One; 2011; 6(8):e24244. PubMed ID: 21909386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.